CHP-MAGE-A4 vaccine study for MAGE-A4-expressing cancer
Phase 1
- Conditions
- MAGE-A4-expressing therapy-resistant cancer (non origin-limited)
- Registration Number
- JPRN-UMIN000001599
- Lead Sponsor
- CHP-MAGE-A4 cancer vaccine study at Mie University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
1.HIV-positives. 2.Double cancers. 3.Autoimmune disease. 4.History of serious hypersensitivity. 5.Active CNS metastasis. 6.Lasting less than four weeks from the previous chemotherapy, systemic corticostoroid, immuno-suppressive or -stimulating agents, radiotherapy, or surgery to primary tumors 7.Pregnant or lactating. 8.Inappropriate for study entry judged by an attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety:maximum-tolerable dose, dose-limting toxicity, profiles of adverse events. Efficacy: MAGE-A4-specific immune responses
- Secondary Outcome Measures
Name Time Method Efficacy:tumor responses, progression-free time, overall survival, response-duration time and time-to-progression